For patients with treatment-naïve advanced renal-cell carcinoma who have intermediate or poor prognostic risk, adding cabozantinib to the combination of nivolumab and ipilimumab significantly prolongs progression-free survival (PFS) compared with the combination alone but at the expense of increased grade 3 or 4 adverse events (AEs), as shown in a phase III trial.